Nasdaq apls.
25 сент. 2023 г. ... Apellis Pharmaceuticals (NASDAQ:APLS) announced Monday that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent ...
2 Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock’s 52-week price range is $33 – $94. The share price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by a huge 60% in the past month, adding to the woes of its shareholders over the last year. Moreover, the stock has not done well, decreasing by 33.33% in the last six months.WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...Stock Quote & Chart. NASDAQ: APLS. $61.58. Dec 1, 2023 4:00 PM EST. Change. +7.71 (+14.31%). Volume. 5,431,264. Today's Open. $53.99. Previous Close. $53.87.WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...
APLS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Apellis Pharmaceuticals, Inc. is based on the …
The public float for APLS is 97.67M, and at present, short sellers hold a 19.04% of that float. On November 06, 2023, the average trading volume of APLS was 3.32M shares. APLS) stock’s latest price update. The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has dropped by -3.80 compared to previous close of 46.83.
If you want to know who really controls Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as ...On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...WALTHAM, Mass. and CRESTWOOD, Ky., June 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...28 de set. de 2022 ... (NASDAQ:APLS) for the first time. The company launched its flagship product Empaveli in 2021 and is currently pursuing other indications ...2 Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock’s 52-week price range is $33 – $94. The share price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by a huge 60% in the past month, adding to the woes of its shareholders over the last year. Moreover, the stock has not done well, decreasing by 33.33% in the last six months.
WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates ...
Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM.Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights. Nov 18, 2023 · A number of firms have modified their ratings and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) recently: 11/9/2023 – Apellis Pharmaceuticals is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $74.00 price target on the stock. 11/2/2023 – Apellis Pharmaceuticals had its price target […] The APLS shares have gain 13.10% over the last week, with a monthly amount glided 10.71%, and seem to be holding up well over. A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $53.87, up 7.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares …Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings results on Wednesday, November, 1st. The company reported ($1.17) earnings per share for the quarter, missing analysts' …
About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq MarketSIte. Do Not Sell My Personal Information (CA...WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its ...Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ...WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...
Apellis Pharmaceuticals (NASDAQ: APLS) 2% HIGHER; BofA Securities upgraded the stock from Neutral to Buy with a price target of $85.00 (from $52.00). After-hours movers: GitLab surges on earnings ...
Analyst Price Forecast Suggests 156.95% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...APLS U.S.: Nasdaq Apellis Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 28, 2023 7:01 p.m. EST Delayed quote $ 46.50 -0.66 -1.40% After Hours Volume: 1... 9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...
Apellis Pharmaceuticals ( NASDAQ:APLS – Get Free Report) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($1.17) EPS for the quarter, missing analysts ...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved t...
Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...Apellis Pharmaceuticals (NASDAQ: APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.. Apellis Pharmaceuticals has announced that it ...Nov 29, 2023 · That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ... Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ...May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ... Apr 24, 2023 · The forecasts range from a low of 51.51 to a high of $148.05. The average price target represents a decrease of 4.25% from its latest reported closing price of 93.18. See our leaderboard of ... APLS Real-Time Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and ... Feb 22, 2023 · With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ... Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Nov 14, 2023 · NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced. CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...A few examples include what’s going on with shares of Yellow Corp (OTCMKTS:YELLQ), Nio (NYSE: NIO), and Apellis Pharmaceuticals (NASDAQ: APLS) stock today. You can catch up on all of that news ...Instagram:https://instagram. best market to day tradelist of sp500 stockssmoke shop insurance companieshwkn WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ... yield on 6 month treasury billbest mortgage lenders dallas WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with ...Empaveli is also approved in Europe under the brand name Aspaveli for the same indication. The drug continues to be one of the growth drivers for Apellis, with … value of bar of gold Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 From $42, Keeps Neutral Rating. Nov. 13. MT. Goldman Sachs Initiates Apellis Pharmaceuticals at Buy Rating With $74 Price Target.MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals...